The European Patent Office (EPO) has approved the company’s patent application concerning the nanoparticles behind the SpagoPix project.

“A strong patent is valuable both for us and for future potential partners. SpagoPix will have exclusivity during many years on the three most important markets; USA, Europe and Japan,” says Mats Hansen, CEO of Spago Nanomedical.

The EPO has issued a so called Intention to grant and the approved patent ”Novel manganese comprising nanostructures” will be valid until at least 2032.

Photo of Mats Hansen: Emil Altonen

Read also:

Interview: Spago Nanomedical – Aiming to improve cancer care